¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

¼¼Á¾´ëÇб³ Çѱ¹Ç÷ÀüÁöÇ÷ÇÐȸ Á¦34Â÷ KSTH Ãß°èÇмú´ëȸ : 2018-09-14

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
¼¼Á¾´ëÇб³ Çѱ¹Ç÷ÀüÁöÇ÷ÇÐȸ Á¦34Â÷ KSTH Ãß°èÇмú´ëȸ : 2018-09-14
±³À°ÀÏÀÚ : 2018-09-14
±³À°Àå¼Ò : ¼¼Á¾´ëÇб³ ¼¼Á¾ÄÁº¥¼ÇȦ ÁöÇÏ1Ãþ ÄÁÆÛ·±½º·ë ¿Ü 2°³·ë  
±³À°ÁÖÁ¦ : Á¦34Â÷ KSTH Ãß°èÇмú´ëȸ      
ÁÖÃÖ±â°ü : Çѱ¹Ç÷ÀüÁöÇ÷ÇÐȸ
´ã´çÀÚ : ±èÁø¾Æ
¿¬¶ôó : 042-484-2426  
À̸ÞÀÏ : ksth@thrombo.or.kr      
±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ¼Ò¾Æû¼Ò³â°ú, Á¤½Å°ú, Á¤Çü¿Ü°ú, ½Å°æ¿Ü°ú, ÈäºÎ¿Ü°ú, À̺ñÀÎÈÄ°ú, ¿µ»óÀÇÇаú, ¸¶ÃëÅëÁõÀÇÇаú, ½Å°æ°ú, ÀçÈ°ÀÇÇаú, °áÇÙ°ú, Áø´Ü°Ë»çÀÇÇаú, º´¸®°ú, °¡Á¤ÀÇÇаú, ÇÙÀÇÇаú, ÀÀ±ÞÀÇÇаúÀÇ»çÇÐ, ¿¹¹æÀÇÇÐ, »ý¸®ÇÐ, ºÐÀÚ»ý¹°ÇÐ, ¹Ì»ý¹°ÇÐ, ÀÇ·á»çȸÇÐ, ÀÇ·áÀ±¸®ÇÐ, ÀÇ·á»çȸ½É¸®ÇÐ, ÀÇ·áÄ¿¹Â´ÏÄÉÀ̼Ç, ÀÇÇб³À°, ÀÇ·áÁ¤Ã¥, ÀÇ·á°æ¿µ, ±âŸ
Âü¼®¿¹»óÀοø : 150¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 6 ½Ã°£ 30ºÐ  
¼¼ºÎ¼ö°­·á : 40,000¿ø      
ºñ°í »çÀüµî·Ïºñ 3¸¸¿ø, Àü°øÀÇ ¹× ±âŸ 1¸¸¿ø      
       
±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09¿ù 14ÀÏ ÄÁÆÛ·±½º·ë2 09:30~10:00 Secondary prevention of recurrent VTE after initial treatment in patients with first unprovoked VTE ¢º assessment for thrombosis and bleeding, prediction model of recurrent VTE, DOACs for secondary prevention  È²Çå±Ô(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 09¿ù 14ÀÏ ÄÁÆÛ·±½º·ë2 10:00~10:30 Selection guide of DOACs and their doses in various clinical situation in patients with VTE  ³ª»óÈÆ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 09¿ù 14ÀÏ ÄÁÆÛ·±½º·ë2 10:30~10:50 Thrombophilia testing in anticoagulated patients  ±èº¸Çö(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 09¿ù 14ÀÏ ÄÁÆÛ·±½º·ë2 10:50~11:10 Lupus anticoagulant; detection guidelines, testing and interpretation  ¹Ú»óÇõ(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 09¿ù 14ÀÏ ÄÁÆÛ·±½º·ë2 11:10~11:30 Heparin induced thrombocytopenia, what should we know  ¼­¿ïÀÇ´ë(±èÇö°æ) 
È޽Ġ09¿ù 14ÀÏ  11:30~11:45 break  () 
±³À°½Ã°£ 09¿ù 14ÀÏ ÄÁÆÛ·±½º·ë2 11:45~12:15 Frontline treatment for chronic ITP  ±èÀ¯¸®(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 09¿ù 14ÀÏ ÄÁÆÛ·±½º·ë2 12:15~12:45 TPO receptor agonist for chronic ITP  ½Åµ¿¿±(¼­¿ïÀÇ´ë) 
½Ä»ç 09¿ù 14ÀÏ  12:45~13:45 Á¡½É½Ä»ç  () 
±³À°½Ã°£ 09¿ù 14ÀÏ ÄÁÆÛ·±½º·ë2 13:45~14:45 cancer VTE; Treatment of Venous thromboembolism in Patient with Cancer  Harry Büller(Academic Medical Center of Amsterdam) 
±³À°½Ã°£ 09¿ù 14ÀÏ ÄÁÆÛ·±½º·ë3 14:45~15:15 Oral presentation  ¹æ¼ö¹Ì,Çö½Å¿µ(¼­¿ïÀÇ´ë,¿¬¼¼´ë ¿øÁÖÀÇ°ú´ëÇÐ) 
È޽Ġ09¿ù 14ÀÏ  15:15~15:30 break  () 
±³À°½Ã°£ 09¿ù 14ÀÏ ÄÁÆÛ·±½º·ë2 15:30~16:00 Anti-platelet activity of Ginseoside Rps and their molecular mechanisms  °æºÏ´ë ¼öÀÇ´ë(À̸¸ÈÖ) 
±³À°½Ã°£ 09¿ù 14ÀÏ ÄÁÆÛ·±½º·ë2 16:00~16:30 Platelet Signaling Pathways: Focus on GPCR  ÃæºÏ´ë ¼öÀÇ´ë(±è¼öÁ¾) 
±³À°½Ã°£ 09¿ù 14ÀÏ ÄÁÆÛ·±½º·ë2 16:30~16:50 Physiology of VWF  ¿¬¼¼ÀÇ´ë(¼ÛÀç¿ì) 
±³À°½Ã°£ 09¿ù 14ÀÏ ÄÁÆÛ·±½º·ë2 16:50~17:10 Characterization of a novel Factor VIII having vWF domain fusion and PEG conjugation  ¸ñ¾Ï»ý¸í°úÇבּ¸¼Ò(¿ÀÀÎÀç) 
±³À°½Ã°£ 09¿ù 14ÀÏ ÄÁÆÛ·±½º·ë2 17:10~17:30 Development of subcutaneous FVIII  ¿¬¼¼ÀÇ´ë(ÇÑÁ¤¿ì) 
±âŸ 09¿ù 14ÀÏ ÄÁÆÛ·±½º·ë2 17:30~17:40 Çмú»ó ¹ßÇ¥ ¹× ½Ã»ó  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ¼¼Á¾´ëÇб³ Çѱ¹Ç÷ÀüÁöÇ÷ÇÐȸ Á¦34Â÷ KSTH Ãß°èÇмú´ëȸ : 2018-09-14""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇѳúÁ¹ÁßÇÐȸ 2018 ICSU 2018 & 1st AKJSC Program(9/13~15) : 2018-09-14
´ÙÀ½±Û ¼øõÇâ´ëÇб³ ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ 2018 °í°üÀý °ñÀý ½ÉÆ÷Áö¿ò : 2018-09-14
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20793 ¼­¿ï ´ëÇÑõ½Ä¾Ë·¹¸£±âÇÐȸ ¾à¹°¾Ë·¹¸£±â ½ÉÆ÷Áö¾ö : 2024-06-15 0 71 2024-05-27
20792 ´ëÀü ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ ´ëÀü, ÃæûÁöȸ - Á¦3Â÷ ¿ù·ÊÁý´ãȸ : 2024-06-15 0 42 2024-05-27
20791 ¼­¿ï Á¦51ȸ ´ëÇÑÀÓ»óÇǺÎÄ¡·á¿¬±¸È¸ ±³À°½ÉÆ÷Áö¾ö : 2024-06-15 0 36 2024-05-27
20790 °æ±â ´ëÇÑÇǺΰúÇÐȸ Á¦52Â÷ ÀÎõºÎõÁöºÎȸ ÇмúÁý´ãȸ : 2024-06-15 0 64 2024-05-27
20789 ¼­¿ï 2024³â ´ëÇѽŰæ±ÙÀ°ÁúȯÇÐȸ ¿¬¼ö°­Á : 2024-06-15 0 36 2024-05-27
20788 Á¦ÁÖ ´ëÇѳ»ºÐºñÇÐȸ Á¦22ȸ ºÐ°úÀü¹®ÀÇ ¿¬¼ö°­Á : 2024-06-15 0 27 2024-05-27
20787 Ãæ³² (¿Â¶óÀÎ)2024³âµµ Ãæû³²µµÀÇ»çȸ Ãá°èÇмú´ëȸ : 2024-06-15 0 43 2024-05-27
20786 ºÎ»ê KSMO ºÎ»ê¿ï»ê°æ³²/´ë±¸°æºÏÁöȸ °øµ¿ ½ÉÆ÷Áö¾ö : 2024-06-14 0 18 2024-05-27
20785 ¼­¿ï 2024³â ´ëÇѺҾÈÀÇÇÐȸ Ãá°èÇмú´ëȸ (´Ù½Ã, °Ü¿ï³ª¹«¿¡¼­ º½ ³ª¹«¿¡·Î From Traditional approaches to Innovation in Psychiatry) : 2024-06-14 0 43 2024-05-27
20784 ¼­¿ï ´ëÇÑ°áÇÙÇùȸ 2024³â °áÇÙ°ü¸®±³À° 1±â(2ÀÏÂ÷) : 2024-06-14 0 30 2024-05-27
20783 ¼­¿ï Á¦14Â÷ Çѱ¹ÃÖ¼Òħ½ÀÃéÀå¼ö¼ú¿¬±¸È¸ : 2024-06-14 0 21 2024-05-27
20782 ´ëÀü 2024 Á¦40ȸ ´ëÇѼҾƿܰúÇÐȸ Ãá°èÇмú´ëȸ ¹× 40Áֳ⠱â³äÇà»ç (2ÀÏÂ÷) : 2024-06-14 0 37 2024-05-27
20781 ´ë±¸ Ä¥°î°æºÏ´ëÇб³º´¿ø RARE DISEASE SYMPOSIUM 2024 : 2024-06-14 0 26 2024-05-27
20780 ºÎ»ê 2024 ´ëÇѽŰæ¿Ü°úÇÐȸ ºÎ»ê¿ï»ê°æ³²Áöȸ Á¦2Â÷ Á¤±âÇмú´ëȸ : 2024-06-14 0 52 2024-05-27
20779 ¼­¿ï 2024 ´ëÇÑÀÇÇÐȸ Çмú´ëȸ : 2024-06-14 0 57 2024-05-27
21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷